Oppenheimer downgraded Vertex Pharmaceuticals (VRTX) to Perform from Outperform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals price target lowered to $400 from $451 at RBC Capital
- Vertex Pharmaceuticals price target lowered to $522 from $545 at BofA
- Vertex Pharma’s suzetrigine meets Phase 2 primary endpoint in radiculopathy
- Vertex Pharmaceuticals price target raised to $494 from $490 at Stifel
- Vertex Pharmaceuticals upgraded to Buy from Hold at Jefferies